Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Invested Capital (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Invested Capital for 10 consecutive years, with $146.4 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 529.0% to $146.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $146.4 million through Dec 2025, up 529.0% year-over-year, with the annual reading at $146.4 million for FY2025, 529.0% up from the prior year.
  • Invested Capital for Q4 2025 was $146.4 million at Rhythm Pharmaceuticals, down from $154.4 million in the prior quarter.
  • The five-year high for Invested Capital was $380.9 million in Q1 2021, with the low at -$8.1 million in Q2 2025.
  • Average Invested Capital over 5 years is $182.0 million, with a median of $189.9 million recorded in 2023.
  • Peak annual rise in Invested Capital hit 1276.49% in 2025, while the deepest fall reached 120.66% in 2025.
  • Over 5 years, Invested Capital stood at $284.2 million in 2021, then fell by 7.0% to $264.3 million in 2022, then tumbled by 35.76% to $169.8 million in 2023, then plummeted by 86.29% to $23.3 million in 2024, then skyrocketed by 529.0% to $146.4 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $146.4 million, $154.4 million, and -$8.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.